Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

The benefits of exercise training in multiple sclerosis.
PICO, PICOS and SPIDER: a comparison study of specificity and sensitivity in three search tools for qualitative systematic reviews.
Reproducibility of Resting State Connectivity in Patients with Stable Multiple Sclerosis.
From injection therapies to natalizumab: views on the treatment of multiple sclerosis.
First-line disease-modifying therapies in paediatric multiple sclerosis: a comprehensive overview.
Microparticles bearing encephalitogenic peptides induce T-cell tolerance and ameliorate experimental autoimmune encephalomyelitis.
Progressive resistance therapy is not the best way to rehabilitate deficits due to multiple sclerosis: No.
Targeting Innate Receptors with MIS416 Reshapes Th Responses and Suppresses CNS Disease in a Mouse Model of Multiple Sclerosis.
Clinically isolated syndromes and the relationship to multiple sclerosis.
Insight into the role of CRMP2 (collapsin response mediator protein 2) in T lymphocyte migration: The particular context of virus infection.
Anti-integrin therapy for multiple sclerosis.
Prevalence of dysphagia in multiple sclerosis: a systematic review and meta-analysis.
RNF and Betaseron® Tolerability Study (REFORMS)
Consensus statements from a panel of u.s. Managed care pharmacists and physicians for management of multiple sclerosis agents.
Genzyme’s Lemtrada® approved in Mexico for treatment of multiple sclerosis
Immune cell trafficking from the brain maintains CNS immune tolerance.
Pharmacokinetics of daclizumab high-yield process with repeated administration of the clinical subcutaneous regimen in patients with relapsing-remitting multiple sclerosis.
Postmarketing Safety Profile of Subcutaneous Interferon Beta-1a Given 3 Times Weekly: A Retrospective Administrative Claims Analysis.
N-Acetylcysteine amide: A Derivative to Fulfill the Promises of N-Acetylcysteine.
Patterns of Retinal Damage Facilitate Differential Diagnosis between Susac Syndrome and MS.
Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study.
Placebo power.
The diagnosis and management of lower urinary tract symptoms in multiple sclerosis patients.
Interleukin-1β alters glutamate transmission at purkinje cell synapses in a mouse model of multiple sclerosis.
The microglial sensome revealed by direct RNA sequencing.

Pages